Nicholas Ranson, MD
Ophthalmology · Traverse City, MINPI 1790783041
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.7%), food and beverage and ownership interests — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Amgen at 59.7% of the total. Reporting peaked in 2020 at $2,275 and has fallen 70.6% since, to $668 in 2025.
Across 47 payments — averaging $95.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- US Retina LLC$667
- Alcon$225
- ANI Pharmaceuticals, Inc.$145
- Tarsus Pharmaceuticals, Inc.$136
- Bausch & Lomb Americas Inc.$135
- plus $505 from 7 others
What the payments were for
- Speaking & faculty fees$2,10047%
- Food & beverage$1,73339%
- Ownership interest$66715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 13 | $2,688 |
| US Retina LLC | 6 | $667 |
| Alcon | 4 | $225 |
| ANI Pharmaceuticals, Inc. | 5 | $145 |
| Tarsus Pharmaceuticals, Inc. | 2 | $136 |
| Bausch & Lomb Americas Inc. | 2 | $135 |
| Dompe US, Inc. | 1 | $125 |
| AbbVie(2 entities) | 5 | $111 |
| Penumbra, Inc. | 1 | $97 |
| Sun Pharmaceutical Industries Inc. | 4 | $75 |
| Oyster Point Pharma, Inc. | 2 | $48 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Lombart Brothers, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,500 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 204 | $2,473 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 197 | $2,211 |
| Doxycycline Hyclate | 16 | $344 |
| Timolol Maleate | 11 | $113 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Traverse City
- Justin TannirTraverse City$21K
- Alicia EbyTraverse City$9K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.